GLP1, SGLT2 and AI in Longevity: Where the Real Value Lies
Background: Biology Meets Commercial Reality Santulli et al. (2024) present a compelling scientific hypothesis: that GLP1 receptor agonists and SGLT2 inhibitors, originally developed for type 2 diabetes, may exert systemic effects relevant to human longevity. These include reductions in cardiovascular and renal risk, anti-inflammatory properties, and potential neuroprotective effects. Concurrently, artificial intelligence is transforming how we […]